AppointmentSomite.ai appoints Shai Kivity as VP Strategy & Operations
Appointment
Somite.ai appoints Shai Kivity as VP Strategy & Operations
Before joining Somite.ai, Kivity served as Chief of Staff and first U.S. employee at 4M Analytics. He joins the company after completing over 250 days of reserve duty in the Iron Swords war as a Deputy Battalion Commander in Gaza.
Israeli TechBio company Somite.ai, a company leveraging big data and AI for its novel cell replacement therapies, has announced it has appointed Shai Kivity as its VP of Strategy & Operations. He brings with him more than a decade of experience in business development, strategy, and operations, and will assist in the growth of the company and lead the development and implementation of its strategy in the global market.
"Shai's joining our team is a significant step towards realizing our vision,” said Dr. Micha Breakstone, CEO and Co-founder of Somite.ai. “Shai shares our passion for developing groundbreaking Israeli technologies and making a positive impact on the world, and he has the skills and experience needed to help us lead the company to the next stage. Shai will lead the development of our strategy, help us accelerate growth, and make Somite AI a leading company in AI-driven drug development. I have been following Shai's brilliant career for a while now and am confident that his addition will advance us to the next stage in the company's life.”
Before joining Somite.ai, Kivity served as Chief of Staff and first U.S. employee at 4M Analytics, where he built the company's international headquarters in Austin, Texas. Prior to that, he led the reorganization of several major companies at Alvarez & Marsal. Before his time at A&M, he served for a decade in the IDF, as part of the Talpiot program in various technological roles, and performed combat service in the Airborn Special Forces. He joins the company after completing over 250 days of reserve duty in the Iron Swords war as a Deputy Battalion Commander in Gaza.
Somite.ai was founded in October 2023 and is developing the AlphaStem platform, which uses AI to enable the discovery and optimization of new therapies, generating massive new data, which in turn leads to new biological discoveries. Recently, it announced the completion of a pre-seed funding round of over $10 million with participation from Astellas Venture Management, the venture capital arm of Japanese pharmaceutical company Astellas, and Montage Ventures, whose representatives joined the company's board as observers.
